Giuseppe Biondi-Zoccai
20 days
In the DanGer Shock randomized trial, including 360 patients with STEMI complicated by cardiogenic shock, Impella reduced 180-day all-cause death from 59% to 46% (p=0.04, NNT=8), and a composite endpoint of escalation of treatment to additional MCS, heart transplantation, or…